产品搜索
结构搜索
全站搜索
在线客服
-
诊断医药客服
当前位置: 技术支持
利塞膦酸盐（105462-24-6）抗男性骨质疏松性骨折的效应
2014-08-27
来源：亚科官网
亚科化学试剂带领大家探讨下利塞膦酸盐（105462-24-6）抗男性骨质疏松性骨折的效应：
方法 通过Medline数据库、EMBASE数据库、Cochrane图书馆和中国生物医学文献数据库检索1980-01至2006-12有关利塞膦酸盐与安慰剂治疗男性骨质疏松患者的随机对照试验.随访大于12个月,提供骨折发生率的文献纳入研究.分析入选文献的方法学质量,提取资料,用RevMan 4.2软件进行荟萃分析.结果 3篇文献符合纳入标准,包括780例男性骨质疏松患者.荟萃分析结果显示利塞膦酸盐可降低69%的椎体骨折风险(RR=0.31,95% CI:0.16,0.60)和58%的非椎体骨折风险(RR=0.42,95% CI:0.23,0.78).结论 利塞膦酸盐对男性骨质疏松症患者可提供良好的抗骨折效应.
参考文献(25条)
Cauley JA,Thompson DE,Ensrud KC. Risk of mortality following clinical fractures[J].Osteoporosis International,2000.556-561.doi:10.1007/s001980070075.
Ross PD. Osteoporosis:frequency,consequences,and risk factors[J].Archives of Internal Medicine,1996.1399-1411.doi:10.1001/archinte.156.13.1399.
Campion JM,Maricic MJ. Osteoporosis in men[J].American Family Physician,2003.1521-1526.
Cooper C,Campion G,Melton LJ 3rd. Hip fractures in the elderly:a world-wide projection[J].Osteoporosis International,1992.285-289.doi:10.1007/BF01623184.
Center JR,Nguyen TV,Schneider D. Mortality after all major types of osteoporotic fracture in men and women:an observational study[J].LANCET,1999.878-882.
Vestergaard P,Rejnmark L,Mosekilde L. Osteoporosis is markedly underdiagnosed:a nationwide study from Denmark[J].Osteoporosis International,2005.134-141.doi:10.1007/s00198-004-1680-8.
Feldstein AC,Nichols G,Orwoll E. The near absence of osteoporosis treatment in older men with fractures[J].Osteoporosis International,2005,(8):953-962.doi:10.1007/s00198-005-1950-0.
Sambrook P,Cooper C. Osteoporosis[J].Lancet,2006.2010-2018.
Palomba S,Orio F Jr,Manguso F. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease[J].Osteoporosis International,2005.1141-1149.doi:10.1007/s00198-005-1927-z.
Kanis JA,Barton IP,Johnell O. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture[J].Osteoporosis International,2005.475-482.doi:10.1007/s00198-004-1698-y.
技术支持：苏州亚科化学试剂 http://www.yacoo.com.cn/
